Skip to main content
Erschienen in: Addiction Science & Clinical Practice 2/2015

Open Access 01.12.2015 | Oral presentation

Value of saliva testing when added to questionnaire screening for unhealthy drug use

verfasst von: H John Saade, Anthony Dedea, Lauren Dedea, Jason Dhabliwala, Andrea T Pusser, J Aaron Johnson, J Paul Seale

Erschienen in: Addiction Science & Clinical Practice | Sonderheft 2/2015

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN

Background

Unhealthy drug use (UDU), including both illicit drug use and misuse of prescription medications, is high among Americans 12 or older (9.4% past month; 48% lifetime), and is often 50-100% higher among emergency department (ED) patients (Cherpitel & Ye, 2008). While most screening, brief intervention and referral to treatment (SBIRT) projects focus on questionnaire screening for UDU, many clinicians are unaware of the potential of saliva testing (ST) to increase detection.
The objective is toassess the added value of ST when added to comprehensive questionnaire screening for UDU.

Material and methods

Research assistants systematically approached adult patients receiving care in the medical-surgical area of an urban ED. After granting informed consent, patients completed a survey containing four different single-item drug screening questions (SDSQs) and the drug use section of the Mini International Neuropsychiatric Interview, then received a financial incentive. Patients granting separate consent then provided a saliva sample for drug testing and received a second incentive.

Results

Among 208 patients interviewed, only 111 (53.4%) agreed to saliva testing. Nine samples were positive in patients not reporting illegal/recreational drug use. Six were positive for prescribed medications which they had reported (five for alprazolam, one for opioids). Two were positive for undisclosed cocaine. One was positive for barbiturates in a patient who did not report barbiturate use.

Conclusions

ST detected two patients (1.8% of those submitting samples) with unsuspected illicit drug use and one patient (0.9%) with unreported prescription psychotropic drug use. Despite financial incentives, 47% of patients refused ST, which could have disclosed more unreported drug use. Results confirm the ability of biomarker testing to detect small numbers of additional patients with potentially life-threatening UDU when added to questionnaire screening.

Acknowledgements

This study was funded by Grant # TI019545 from the Substance Abuse and Mental Health Services Administration (SAMHSA), USA. The authors also wish to acknowledge the assistance from all the faculty and staff at the Family Health Center, Macon, GA, USA with especial appreciation to the Behavioral Sciences Department.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​4.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
Literatur
1.
Zurück zum Zitat Cherpitel CJ, Ye Y: Drug use and problem drinking associated with primary care and emergency room utilization in the US general population: data from the 2005 national alcohol survey. Drug alcohol depend. 2008, 97: 226-230. 10.1016/j.drugalcdep.2008.03.033.PubMedCentralCrossRefPubMed Cherpitel CJ, Ye Y: Drug use and problem drinking associated with primary care and emergency room utilization in the US general population: data from the 2005 national alcohol survey. Drug alcohol depend. 2008, 97: 226-230. 10.1016/j.drugalcdep.2008.03.033.PubMedCentralCrossRefPubMed
Metadaten
Titel
Value of saliva testing when added to questionnaire screening for unhealthy drug use
verfasst von
H John Saade
Anthony Dedea
Lauren Dedea
Jason Dhabliwala
Andrea T Pusser
J Aaron Johnson
J Paul Seale
Publikationsdatum
01.12.2015
Verlag
BioMed Central
Erschienen in
Addiction Science & Clinical Practice / Ausgabe Sonderheft 2/2015
Elektronische ISSN: 1940-0640
DOI
https://doi.org/10.1186/1940-0640-10-S2-O25

Weitere Artikel der Sonderheft 2/2015

Addiction Science & Clinical Practice 2/2015 Zur Ausgabe